Clozapine plus smoking (and quitting smoking)

The mechanism

CYP1A2 is induced by polycyclic aromatic hydrocarbons (PAHs) in cigarette smoke, not by nicotine. This means:

• Nicotine replacement therapy (patches, gum, lozenges) does not maintain CYP1A2 induction because it does not deliver PAHs.
• Vaping devices (electronic cigarettes) probably do not maintain CYP1A2 induction, though data is limited.
• Cannabis smoking may induce CYP1A2 similarly to tobacco (from the smoke itself), but data is less robust.

Clozapine is metabolized primarily by CYP1A2 (with minor contributions from CYP3A4 and CYP2D6). Smoker vs non-smoker plasma clozapine concentrations differ substantially at the same dose.

What the numbers look like

Smokers on clozapine: at the same dose, plasma clozapine concentrations are 30 to 50 percent lower than in non-smokers.

Dose adjustment for smokers: to achieve the same target level, smokers typically need clozapine doses 50 percent higher than non-smokers. A non-smoker on 300 mg/day might need 450 mg/day if they were smoking.

After smoking cessation: CYP1A2 activity returns to baseline over 4 to 6 weeks. Plasma clozapine levels rise correspondingly. Level rises of 50 to 100 percent have been documented.

Clinical scenarios that go wrong

The classic case: Long-term smoker with schizophrenia on 500 mg/day clozapine is admitted to a smoke-free psychiatric hospital or medical hospital. Over 2 to 3 weeks, they develop sedation, hypotension, orthostasis, and in some cases seizures or new agranulocytosis. Clozapine level, which was fine before, is now toxic. The connection to smoking cessation is not always made.

The gradual quit: Patient on stable clozapine gradually cuts down smoking over months. Clozapine level rises slowly. Side effects escalate slowly. Not always attributed to smoking change.

Illness-related quit: Patient with respiratory illness (pneumonia, COVID) reduces or stops smoking during hospitalization. Clozapine effect changes.

Post-discharge relapse: Patient stops smoking during inpatient stay, clozapine dose is not adjusted, they resume smoking after discharge, and clozapine level drops with resulting inadequate psychosis control.

Management

When a clozapine patient stops smoking:

• Check clozapine level within 1 to 2 weeks of cessation
• Consider empirical dose reduction of 25 to 30 percent at cessation
• Recheck level at 4 and 8 weeks
• Adjust dose based on level and clinical response
• Monitor for sedation, hypotension, seizures, and cardiac symptoms

When a clozapine patient starts smoking:

• Level will drop
• Consider empirical increase of 30 to 50 percent
• Recheck level in 2 to 4 weeks
• Adjust as needed

When a clozapine patient starts nicotine replacement or vaping without tobacco:

• Same effect as cessation (nicotine does not induce CYP1A2)
• Manage as cessation

When a clozapine patient starts varenicline (Chantix) for smoking cessation:

• No known direct interaction with clozapine
• Follow the cessation protocol above

When a clozapine patient starts bupropion for smoking cessation:

• Bupropion lowers seizure threshold and clozapine also carries seizure risk
• Combination is not absolutely contraindicated but seizure risk is elevated
• Standard smoking cessation with nicotine replacement or varenicline is often preferred

Other CYP1A2 substrates affected

Olanzapine: smokers metabolize olanzapine faster. Cessation raises levels moderately (30 to 50 percent). Same monitoring principle applies but effect is smaller than clozapine.

Duloxetine: modest smoking effect.

Caffeine: half-life extends significantly with cessation. New non-smokers often report much more caffeine sensitivity for weeks after quitting.

Theophylline: substantial interaction with smoking status.

Ropinirole, tacrine: also CYP1A2 substrates.

Common questions

Do I need to smoke to keep my clozapine working? No. You need the right dose for your smoking status. If you quit, the dose can be reduced to keep the same blood level. Quitting is a legitimate goal that requires dose adjustment, not a reason to keep smoking.

Does vaping count as smoking for clozapine? Probably not, though data is limited. Nicotine vapes do not deliver the PAHs that induce CYP1A2. If a patient switches from combustible tobacco to vaping, treat it as cessation for clozapine monitoring purposes.

What about cannabis smoking? Cannabis smoke contains PAHs from combustion, so it likely induces CYP1A2 to some degree. Data is much less robust than for tobacco. Cannabis edibles do not have this effect.

How fast does CYP1A2 recover after quitting? Roughly 4 to 6 weeks to reach the new baseline. Some effect within days as the residual induction diminishes.

Should I check a clozapine level any time a patient is admitted to the hospital? Yes if they are on clozapine and either had to stop smoking or their smoking pattern changed. Even brief cessation during hospitalization can change levels.

Does the same problem apply to olanzapine? Yes, but the effect is smaller. Olanzapine doses may need adjustment (10 to 30 percent) with smoking status change. Less clinically urgent than clozapine but still relevant, especially in patients with tight symptom control.

What about smoking cessation medications for a clozapine patient? Nicotine replacement (patch, gum, lozenge) is preferred first-line and does not induce CYP1A2. Varenicline is acceptable. Bupropion is possible but adds seizure risk. Behavioral support (counseling) is always appropriate.

Sources

• Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62(12):1049-1053.
• Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol. 2001;21(6):569-574.
• de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):1059-1063.
• FDA prescribing information for clozapine.
• Wagner E, Kane JM, Correll CU, et al. Clozapine combination and augmentation strategies in patients with schizophrenia: recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophr Bull. 2020;46(6):1459-1470.